Kamada Ltd. (NASDAQ: KMDA) is a leading international biopharmacy company that specializes in the development, production, and marketing of a wide range of plasma-derived protein therapeutics. Its operations are focused on orphan indications and immune and metabolic diseases. With headquarters in Rehovot, Israel, and commercialization across the globe, Kamada has continuously illustrated an unwavering commitment to addressing unmet patient needs and improving health outcomes.
Founded in 1990, the company has steadily grown to become an influential player in the global healthcare industry. Kamada takes a unique and innovative approach to its operations. By utilizing its proprietary platform technology, the company can deliver high-quality therapeutic proteins with improved pharmacokinetic, immunologic, and safety profiles.
The company operates via two segments – Proprietary Products, which develops, manufactures, and markets proprietary plasma-derived pharmaceuticals; and Distribution, which provides end-to-end solutions to international customers, including plasma collection, product development and registration, and more. Its flagship product is Glassia – the first-ever liquid, ready-to-use, intravenous plasma-derived AAT product approved by the US FDA.
Kamada’s product portfolio is known for its remarkable efficacy in treating a variety of conditions. Whether it’s an antitrypsin deficiency, which can lead to lung and liver diseases, or rabies, the company's range of plasma-derived protein therapeutics addresses an extensive array of health problems. Kamada is also a primary supplier of specialty plasma-derived hyperimmunoglobulins and various biological entities for biotherapy shortages.
As a company that hinges on strong partnerships, Kamada has strategic alliances with a variety of pharmaceutical industry leaders, including Takeda, Covance, Baxter, and Chiesi Farmaceutici.
In recent years, Kamada has also shown a commitment to environmental, social, and governance (ESG) factors, recognizing that significant impact on human health begins with sustainable and ethical business practices. The company is dedicated to reducing its environmental footprint, investing in its employees, contributing to society, and maintaining the highest standards of corporate governance.
Through a rich pipeline and consistent investment in research and development, Kamada maintains its position as a leading global-specialty plasma-focused bio-pharmaceutical company. It's commitment to enhancing patient healthcare systems worldwide while maintaining a responsibility toward a sustainable future truly sets Kamada Ltd. apart in the international healthcare industry.